Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

INTRODUCTION: Predictive cancer biomarkers to guide the right treatment to the right patient at the right time are strongly needed. The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A c...

Descripción completa

Detalles Bibliográficos
Autores principales: Munro, Alison F, Bartels, Annette, Balslev, Eva, Twelves, Christopher J, Cameron, David A, Brünner, Nils, Bartlett, John MS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672718/
https://www.ncbi.nlm.nih.gov/pubmed/23570501
http://dx.doi.org/10.1186/bcr3411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672718/
https://www.ncbi.nlm.nih.gov/pubmed/23570501
http://dx.doi.org/10.1186/bcr3411

Ejemplares similares